Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Japanese adult males
jRCT2090220109Phase 1Unknown
- Sponsor
- Myoia
- Start
- Jan 2013
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of BK-SE36 + CpG in Malaria (2 arms), sponsored by Myoia. Primary endpoint: Safety of BK-SE36/CpG. Status: unknown.
02
Drugs
BK-SE36 + CpG
03
Conditions
Malaria
Beyond the preview
Go deeper on jRCT2090220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2090220109.